Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (Blakemore 2010; Helb 2010).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Helb 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
From Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens (2011) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,973
The association for the advancement of medical instrumentation
(1974) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(74)90035-0 · Cited by 1,031
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525 · cited 1×
“tuberculosis detection (15), this assay was too complex and too prone to operator errors, sample cross-contamination, and biohazards for rapid near-patient use.”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 3×
“Truly rapid results for drug susceptibility tests are particularly important in the management of drug-resistant tuberculosis (13).”
BackgroundMicroscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Cited by
Items 401–500 of 940
Diagnosis of pulmonary tuberculosis in a microbiological laboratory
Khéchine, A. E., & Drancourt, M. (2011) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2011.07.012 · Cited by 20
Lira, L. A. S., Santos, F. C. F., Carvalho, M. S., Montenegro, R., Lima, J. F. C., Schindler, H. C., & Montenegro, L. M. L. (2012) · Journal of Applied Microbiology · doi:10.1111/jam.12119 · Cited by 20
“tuberculosis transmission, TB incidence and resistance to drugs (Helb et al. 2010).”
BackgroundAccuracy of LAMP-TB Method for Diagnosing Tuberculosis in Haiti
Kaku, T., Minamoto, F., D'Meza, R., Morose, W., Boncy, J., Bijou, J., Geffrard, H., Yoshida, M., & Mori, T. (2016) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2015.519 · Cited by 20
“GeneXpert (Cepheid, Sunnyvale, CA, USA) is another system of POC NAA that has been endorsed by the WHO and is widely used (13).”
ResultThermal lysis and isothermal amplification of Mycobacterium tuberculosis H37Rv in one tube
Shetty, P., Ghosh, D., & Paul, D. (2017) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2017.09.013 · Cited by 20
Zewdie, O., Mihret, A., Abebe, T., Kebede, A., Desta, K., Worku, A., & Ameni, G. (2017) · New Microbes and New Infections · doi:10.1016/j.nmni.2017.10.009 · Cited by 20
“Recently, WHO recommended the use of molecular techniques such as line probe assay and GeneXpert assay for rapid screening of MDR-TB to evaluate the presence of genomic mutations conferring resistance in MDR-TB [6,7].”
MethodCorrection: A Handheld Point-of-Care Genomic Diagnostic System
Myers, F. B., Henrikson, R. H., Bone, J. M., & Lee, L. P. (2013) · PLoS ONE · doi:10.1371/annotation/902dc1bb-9ed7-4e91-a550-0f0a87ce17ba · Cited by 20
Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections
Ouyang, X., Li, X., Song, J., Wang, H., Wang, S., Ren, F., Li, Z., & Song, N. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1277178 · Cited by 20
Translating nucleic-acid hybridization into universal DNA-reporter sequences
Ravan, H. (2014) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2014.09.012 · Cited by 19
Lu, J. L., Zheng, H., Chu, P., Han, S., Yang, H. Q., Wang, Z., Shi, J. P., & Yang, Z. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22716 · Cited by 19
Tuberculosis Diagnostics: State of the Art and Future Directions
Pai, M., Nicol, M. P., & Boehme, C. C. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch16 · Cited by 22
Self-citationJauset‐Rubio, M., Ortiz, M., & O’Sullivan, C. K. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03419 · Cited by 19
Current Developments and Future Perspectives For Tb Diagnostics
Palomino, J. C. (2011) · Future Microbiology · doi:10.2217/fmb.11.133 · Cited by 21
Santos, V. S., Allgayer, M. F., Kontogianni, K., Rocha, J. E., Pimentel, B. J., Amorim, M. T. P., Duarte, M. V. S. C., Ferreira, P. D. M., Moura, L. C. L., de Lima, V. P. S., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.01.009 · Cited by 20
“positive results during pooled testing (Helb et al. 2010; Chakravorty et al. 2017).”
Walter, N. D., Strong, M., Belknap, R., Ordway, D. J., Daley, C. L., & Chan, E. D. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02176.x · Cited by 20
Molecular characterisation of rifampicin-resistant Mycobacterium tuberculosis strains from Malawi
Chikaonda, T., Ketseoglou, I., Nguluwe, N., Krysiak, R., Thengolose, I., Nyakwawa, F., Rosenberg, N. E., Stanley, C., Mpunga, J. A., Hoffman, I., et al. (2017) · African Journal of Laboratory Medicine · doi:10.4102/ajlm.v6i2.463 · Cited by 20
Emane, A. K. A., Pierre-Audigier, C., Biyogo, O. C. A., Nzoghe, A. M., Cadet-Daniel, V., Sola, C., Siawaya, J. F. D., Gicquel, B., & Takiff, H. E. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02257-16 · Cited by 18
“In contrast, the bacilli in samples processed for the Xpert assay are no longer viable (31), so they can be used in PCRs without any special infrastructure.”
MethodMbelele, P. M., Aboud, S., Mpagama, S. G., & Matee, M. I. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2931-6 · Cited by 18
“For example, the estimated detection limit of Xpert is 131 colonies forming unit (CFU)/ml, while LJ culture is 10– 100 CFU/ml [27].”
BackgroundPhetsuksiri, B., Klayut, W., Rudeeaneksin, J., Srisungngam, S., Bunchoo, S., Toonkomdang, S., Wongchai, T., Nakajima, C., & Suzuki, Y. (2020) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202062036 · Cited by 18
Worku, G., Gumi, B., Girma, M., Berhe, B. M., Diriba, G., Seid, G., Getu, M., Amare, M., Sinshaw, W., Ashagre, W., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.942618 · Cited by 18
“The assays detect mutations in the 81-base-pair rpoB gene, which is linked to RIF resistance in 95–98% of cases (5).”
BackgroundMethodPierneef, L., van Hooij, A., de Jong, D., Fat, E. M. T. K., van Meijgaarden, K. E., Petruccioli, E., Vanini, V., Roukens, A. H. E., Goletti, D., Corstjens, P. L. A. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105873 · Cited by 18
“TB diagnostic services are not sufficiently accessible, as exemplified by the fact that the WHO endorsed Xpert MTB/RIF (GeneXpert; Cepheid Inc., Sunnyvale, CA, USA) test for TB 17,18 is not sufficiently available to people living in remote, TB endemic areas.”
Les tests bactériologiques de la tuberculose maladie : standards et perspectives
Truffot-Pernot, C., & Véziris, N. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.07.002 · Cited by 23
Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV‐infected patients
Ablanedo‐Terrazas, Y., Alvarado‐de la Barrera, C., Hernández‐Juan, R., Ruiz‐Cruz, M., & Reyes‐Terán, G. (2014) · The Laryngoscope · doi:10.1002/lary.24478 · Cited by 13
“The Xpert assay was performed as described previously.(13) A 2:1 volume of sample reagent buffer was added to very small”
MethodNicol, M. P., Whitelaw, A. C., & Stevens, W. S. (2013) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x113099990015 · Cited by 18
Zenteno‐Cuevas, R., Cuevas-Córdoba, B., Enciso, J. A., Enciso, L., & Cuellar, A. (2012) · Canadian Journal of Microbiology · doi:10.1139/w11-127 · Cited by 19
“A considerable number of such probes exist, each with different properties and characteristics, and these have already been utilized in the diagnosis of resistance to rifampin and isoniazid through the identification of specific mutations in the genes rpoB and katG (García de Viedma et al. 2002; van Doorn et al. 2003;…”
BackgroundRapid molecular detection of tuberculosis
Zbinden, A. C., Keller, P. M., & Bloemberg, G. V. (2011) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-46070 · Cited by 18
Massi, M. N., Biatko, K. T., Handayani, I., Pratama, M. Y., Septriani, S., Nurdin, G. M., & Ali, M. B. (2017) · Journal of Orthopaedics · doi:10.1016/j.jor.2016.12.003 · Cited by 18
“GeneXpert MTB/RIF test is conducted using a modified Helb method.(18) A specimen of vertebral bone that contains blood, pus, and tissues from spinal surgery will be crushed and centrifuged for 10 min.”
MethodPereira, G. R., Barbosa, M. S., Dias, N. J. D., de Almeida, C. P. B., & Silva, D. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193988 · Cited by 18
Vinuesa, V., Borrás, R., Briones, M. L., Clari, M. Á., Cresencio, V., Giménez, E., Muñoz, C., Oltra, R., Servera, E., Carabelli, T. S., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00116-18 · Cited by 19
Prakash, A. K., Datta, B., Tripathy, J. P., Kumar, N., Chatterjee, P., & Jaiswal, A. (2018) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2018.05.021 · Cited by 18
Kargupta, R., Puttaswamy, S., Lee, A. J., Butler, T. E., Li, Z., Chakraborty, S., & Sengupta, S. (2017) · Biological Research · doi:10.1186/s40659-017-0126-7 · Cited by 17
“The Xpert MTB/RIF is a nucleic acid amplification technique that can detect the presence of mycobacteria in less than 2 h, and has a limit of detection of 131 CFU/ml in sputum [9].”
MethodMycobacterial biomaterials and resources for researchers
Hazbón, M. H., Rigouts, L., Schito, M. L., Ezewudo, M. N., Kudo, T., Itoh, T., Ohkuma, M., Kiss, K., Wu, L., Ma, J., et al. (2018) · Pathogens and Disease · doi:10.1093/femspd/fty042 · Cited by 17
A retrospective study on Xpert MTB/RIF for detection of tuberculosis in a teaching hospital in China
Li, S., Lin, L., Zhang, F., Zhao, C., Meng, H., & Wang, H. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05004-8 · Cited by 17
Esmail, A., Pooran, A., Sabur, N. F., Fadul, M., Brar, M. S., Oelofse, S., Tomasicchio, M., & Dheda, K. U. J. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01032-20 · Cited by 17
“mated, sputum-based, real-time PCR assay that permits rapid identification of Mycobacterium tuberculosis and determination of rifampicin resistance (7).”
Hameed, H. M. A., Fang, C., Liu, Z., Ju, Y., Han, X., Gao, Y., Wang, S., Chiwala, G., Tan, Y., Guan, P., et al. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s375869 · Cited by 17
Tuberculosis: From an Untreatable Disease in Antiquity to an Untreatable Disease in Modern Times?
Boire, N. A. (2013) · Journal of Ancient Diseases & Preventive Remedies · doi:10.4172/2329-8731.1000106 · Cited by 17
Elhassan, M. M., Hemeg, H. A., Elmekki, M. A., Turkistani, K. A., & Abdul-Aziz, A. A. (2017) · Infectious Disorders - Drug Targets · doi:10.2174/1871526517666161116104242 · Cited by 17
“The urgent need for a rapid and easily applicable method of MDR detection is raised by the increase in the global incidence of MDR TB [11].”
MethodThe Use of Selected Commercial Molecular Assays for the Microbiological Diagnosis of Tuberculosis
Safianowska, A., Walkiewicz, R., Nejman‐Gryz, P., & Grubek-Jaworska, H. (2011) · Advances in respiratory medicine · doi:10.5603/arm.27611 · Cited by 17
“[15] conclude that the Xpert MTB/RIF system is characterised by a high specificity and the ability to detect MTBC strains even in samples contaminated with non-tuber-”
BackgroundMartin, I. C., Hakizayezu, F., Ahmed, A., Runyambo, D., Niyompano, H., Keysers, J., de Rijk, W. B., Mulders, W., Mitchell, E. M. H., Decroo, T., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf132 · Cited by 20
“The roll-out of Xpert MTB/RIF (Cepheid, USA) has been pivotal, offering rapid and robust TB diagnosis with simultaneous RR detection [2].”
Wells, C. D. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0104-5 · Cited by 16
“The specimen processing required by these technologies is being ever more simplified to allow for easier uptake and incorporation into general laboratory use [30, 31 ].”
MethodBranavan, M., Mackay, R. E., Craw, P., Naveenathayalan, A., Ahern, J. C., Sivanesan, T., Hudson, C., Stead, T., Kremer, J., Garg, N., et al. (2016) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2016.04.022 · Cited by 16
“Whilst a number of companies have developed point of are devices, for example the Cepheid GeneXpert, Biofire Filmarray nd the LIAT analyser, all of the systems are benchtop, require ains power and some hands on sample preparation [3-6] .”
BackgroundPropidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells
Kayigire, X. A., Friedrich, S. O., Karinja, M. N., van der Merwe, L., Martinson, N. A., & Diacon, A. H. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.08.006 · Cited by 16
“The magnitude of the CT value of each probe depends on the amount of target DNA present in the sample.”
InfluentialNovel Primer-Probe Sets for Detection and Identification of Mycobacteria by PCR-Microarray Assay
Lazzeri, E., Santoro, F., Oggioni, M. R., Iannelli, F., & Pozzi, G. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02300-12 · Cited by 16
“Many different assays have been developed for the molecular diagnosis of mycobacterial infections (5, 6, 10, 14).”
BackgroundA point-of-care instrument for rapid multiplexed pathogen genotyping
Myers, F. B., Henrikson, R. H., Xu, L., & Lee, L. P. (2011) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2011.6090619 · Cited by 16
Tuberculosis 2: Pathophysiology and microbiology of pulmonary tuberculosis
Wani, R. L. S. (2013) · South Sudan Medical Journal · Cited by 16
Asencios, L., Galarza, M., Quispe, N., Vásquez, L., Leo, E. D., Valencia, E., Ramírez, J. D., Acurio, M., Salazar, R., Mendoza‐Ticona, A., et al. (2012) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.1590/s1726-46342012000100014 · Cited by 33
“La elevada sensibilidad de la prueba molecular para detectar resistencia a rifampicina puede explicarse por el hecho de que las principales mutaciones de resistencia se encuentran en la región core de 81pb recientemente el método de GeneXpert (15,16) han probado ser metodologías muy sensibles, específicas y rápidas pa…”
BackgroundMustapha, G., Jumoke, O., Nwadike, P., Emeka, E., Akang, G., Eneogu, R. A., Chukwueme, N., Aliyu, G. G., & Bhatta, G. K. (2016) · SAARC Journal of Tuberculosis Lung Diseases and HIV/AIDS · doi:10.3126/saarctb.v12i2.15948 · Cited by 16
Efficacy and role of Xpert ® Mycobacterium tuberculosis/rifampicin assay in urinary tuberculosis
Kekre, N., Samuel, B. P., Michael, J. S., Chandrasingh, J., Kumar, S., & Devasia, A. (2018) · Indian Journal of Urology · doi:10.4103/iju.iju_189_18 · Cited by 16
“The technical aspects of the GeneXpert system has been well described by several authors.[6]”
MethodSharma, K., Gupta, A., Sharma, M., Sharma, A., Bansal, R., Sharma, S. P., Singh, R. D., & Gupta, V. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1655581 · Cited by 16
Molecular Logic Gates for DNA Analysis: Detection of Rifampin Resistance in M. tuberculosis DNA
Cornett, E. M., Campbell, E. A., Gulenay, G., Peterson, E., Bhaskar, N., & Kolpashchikov, D. M. (2012) · Angewandte Chemie · doi:10.1002/ange.201203708 · Cited by 17
Kammoun, S., Smaoui, S., Marouane, C., Slim, L., & Messadi-Akrout, F. (2015) · International Journal of Mycobacteriology · doi:10.4103/2212-5531.201450 · Cited by 16
de Brito, G. M. X., Mafort, T. T., Alves, M. R., dos Reis, L. V. T., Leung, J., Leão, R. S., Rufino, R., & Rodrigues, L. S. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20200581 · Cited by 19
“tuberculosis and of resistance to rifampin.(9,10) The Xpert MTB/RIF assay has proven to have high sensitivity and specificity, as well as being a test of low complexity that is safe and cost-effective for the diagnosis and management of suspected cases of tuberculosis.”
BackgroundMpagama, S. G., Mtabho, C., Mwaigwisya, S., Mleoh, L., Boer, M. S., Heysell, S. K., Houpt, E. R., & Kibiki, G. S. (2012) · Tuberculosis Research and Treatment · doi:10.1155/2012/128057 · Cited by 15
Zhao, Y. X., Li, G., Sun, C., Li, C., Wang, X., Liu, H., Zhang, P., Zhao, X., Wang, X., Jiang, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143444 · Cited by 15
“According to the reports [14], a total of 23 common rpoBmutations associated with RFP-resistantM.”
BackgroundMethodInfluentialDharan, N. J., Blakemore, R., Sloutsky, A., Kaur, D., Alexander, R. C., Ghajar, M., Musser, K. A., Escuyer, V. E., Rowlinson, M., Crowe, S., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-2039-4 · Cited by 17
“Background The Xpert MTB/RIF (Xpert) assay [1, 2] detects the presence of Mycobacterium tuberculosis complex DNA (MTBc) and mutations associated with resistance to rifampin (RIF) in clinical samples in under two hours.”
MethodSelf-citationBanada, P. P., Deshpande, S., Russo, R., Singleton, E., Shah, D., Patel, B., Burday, M., Koshy, R., Wang, Q., Jones, M., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00466-17 · Cited by 15
“In contrast, the GeneXpert system detects pathogens using a simple plastic cartridge that integrates sample processing and target detection and requires few manual steps to perform (9, 15, 16).”
MethodSelf-citationAl-Hrazi, R. M. A., Al-Shamahy, H. A., & Jaadan, B. M. (2019) · Universal Journal of Pharmaceutical Research · doi:10.22270/ujpr.v4i3.266 · Cited by 16
McIvor, A., Gordhan, B. G., Waja, Z., Otwombe, K. N., Martinson, N. A., & Kana, B. D. (2021) · Tuberculosis · doi:10.1016/j.tube.2021.102103 · Cited by 16
Omar, S. V., Roth, A. J., Ismail, N. A., Erasmus, L., Ehlers, M. M., Kock, M. M., Paulse, N., Said, H. M., Hoosen, A. A., & Reischl, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024789 · Cited by 15
Cortez, M. V., de Oliveira, C. M. C., Monte, R. L., Araújo, J. R., Braga, B. B., dos Reis, D. Z., Ferreira, L. C., Moraes, M. O., & Talhari, S. (2011) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962011000500010 · Cited by 15
Avashia, S., Bansal, D. D., Ahuja, K., & Agrawal, D. V. (2016) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2016.i02.010 · Cited by 15
Recent Innovations in Diagnosis and Treatment of Pediatric Tuberculosis
Gaensbauer, J. T., & Broadhurst, R. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0662-0 · Cited by 15
Successful Treatment of Rifampicin-resistant Intraocular Tuberculosis
Sharma, K., Bansal, R., Sharma, A., Gupta, A., & Fiorella, P. D. (2014) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.888084 · Cited by 15
“Simultaneous detection of MTB infection and rifampicin resistance has been made possible by Xpert MTB/RIF assay.(11) More than 95% of rifampi-”
Highsmith, H. Y., Starke, J. R., & Mandalakas, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00029-8 · Cited by 15
Widespread Foodborne Cyclosporiasis Outbreaks Present Major Challenges
Colley, D. G. (1996) · Emerging infectious diseases · doi:10.3201/eid0204.960413 · Cited by 16
(2012) · PubMed · Cited by 14
Integrated nucleic acid testing system to enable TB diagnosis in peripheral settings
Lu, H., Sakamuri, R. M., Kumar, P., Ferguson, T. M., Doebler, R. W., Herrington, K., Talbot, R., Weigel, K. M., Nguyen, F. K., Cangelosi, G. A., et al. (2020) · Lab on a Chip · doi:10.1039/d0lc00445f · Cited by 14
Nataraj, G., Kanade, S. R., Mohammed, Z., & Kulkarni, A. (2023) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_86_23 · Cited by 14
Mutingwende, I., Vermeulen, U., Steyn, F., Viljoen, H. J., & Grobler, A. (2015) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2015.06.007 · Cited by 15
La tuberculose multirésistante : extension, menace et solutions
Jp, Z. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.10.040 · Cited by 14
Tran, S. T., Renschler, J. P., Le, H. T., Dang, H. T. T., Dao, T. M., Pham, A. N., Liêm, N. T., Nguyen, H. V., Nguyen, T. T. T., Le, S. N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072100 · Cited by 16
Zhang, T., Hu, S.-Y., Li, G., Li, H., Liu, X., Niu, J., Wang, F., Wen, H., Xu, Y., & Li, Q. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.12.004 · Cited by 14
“outbreaks, increased mortality, and resistance to additional anti-TB drugs [1,2].”
BackgroundDevelopment of imaging techniques to study the pathogenesis of BSL 2/3 infectious agents
Rella, C. E., Ruel, N., & Eugenín, E. A. (2014) · Pathogens and Disease · doi:10.1111/2049-632x.12199 · Cited by 14
“Tuberculosis, a BSL3 pathogen, is a diagnostically challenging pathogen that can undergo latency, in which it essentially hides in a host cell; thereby, evading easy detection (Helb et al., 2010; Antonenka et al., 2013).”
BackgroundGene Xpert MTB/RIF Assay: A New Hope for Extrapulmonary Tuberculosis
Raj, A. (2012) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-02108389 · Cited by 15
Ou, X., Wang, S., Dong, H., Pang, Y., Li, Q., Xia, H., Qu, Y., Zhang, Z., Li, J., Zhang, J. Y., et al. (2016) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2016.07.008 · Cited by 14
Shrestha, P. S., Khanal, H., Dahal, P., & Dongol, P. (2018) · The Open Microbiology Journal · doi:10.2174/1874285801812010009 · Cited by 14
Mathebula, U., Emerson, C., Agizew, T., Pals, S., Boyd, R. C., Mathoma, A., Basotli, J., Rankgoane-Pono, G., Serumola, C., Date, A. A., et al. (2020) · Public Health Action · doi:10.5588/pha.19.0051 · Cited by 14
Detection of Heteroresistant Mycobacterium tuberculosis by Pyrosequencing
Engström, A., Hoffner, S. E., & Juréen, P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01761-13 · Cited by 14
Chamberland, M. E., Epstein, J. S., Dodd, R. Y., Persing, D. H., Will, R. G., DeMaria, A., Emmanuel, J., Pierce, B., & KHABBAZ, R. F. (1998) · Emerging infectious diseases · doi:10.3201/eid0403.980317 · Cited by 15
Self-citationKim, H., Kwak, N., Yoon, S. H., Park, N., Kim, Y. R., Lee, J. H., Lee, J. Y., Park, Y., Kang, Y. A., Kim, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63885-0 · Cited by 19
“Its cycle threshold (Ct) value offers a semi-quantitative measure of bacillary burden in sputum, with a one-cycle increase indicating a 50% reduction in MTB DNA 10–12 .”
BackgroundMethodMycobacteriumdiagnostics: from the primitive to the promising
O’Connor, J. A., O'reilly, B., Corcoran, G. D., O’Mahony, J., & Lucey, B. (2015) · British Journal of Biomedical Science · doi:10.1080/09674845.2015.11666793 · Cited by 13
Çelik, C., Gözel, M. G., Bakıcı, M. Z., Berk, S., Özşahin, S. L., & Gültürk, E. A. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1407-56 · Cited by 13
“6% for negative microscopy and positive culture specimens (23).”
BackgroundMethodInfluentialWhole-Genome Sequencing of Mycobacterium tuberculosis Directly from Sputum Samples
Brown, A. C. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1460-0_20 · Cited by 13
Bai, W., Liu, L., Wu, L., Chen, S., Wu, S., Wang, Z., Xu, K., Chi, Q., Pan, Y., & Xu, X. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24154 · Cited by 13
Deng, Y., Ma, Z., Su, B., Bai, G., Pan, J., Wang, Q., Cai, L., Song, Y., Shang, Y., Ma, P., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2151382 · Cited by 13
Sailo, C. V., Lalremruata, R., Sanga, Z., Fela, V., Kharkongor, F., Chhakchhuak, Z., Chhakchhuak, L., Nemi, L., Zothanzama, J., & Kumar, N. S. (2022) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2022.100342 · Cited by 13
Diagnosis of paediatric tuberculosis: the culture conundrum
Dodd, L. E., & Wilkinson, R. J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70290-6 · Cited by 13
An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF
Çaycı, Y. T., Bılgın, K., Çoban, A. Y., Bırıncı, A., & Durupınar, B. (2017) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760170051 · Cited by 13
“One of these molecular techniques is Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) which is a rapid, automated, and cartridge-based genotypic test that can simultaneously detect Mycobacterium tuberculosis complex (MTBC) and RIF resistance (Helb et al. 2010).”
MethodGoud, K. I., Matam, K., Madasu, A. M., Vempati, R., Alodhayani, A. A., Mohammed, A. A., & Khan, I. A. (2020) · African Health Sciences · doi:10.4314/ahs.v20i4.14 · Cited by 13
The management of tuberculosis: epidemiology, resistance and monitoring.
Bang, D. (2010) · PubMed · Cited by 18
Rahman, S. M. M., Nasrin, R., Kabir, S., Kabir, F., Rahman, M. A., Uddin, M. K. M., Islam, A. S. M. I., Khatun, R., Ahmed, S., Mondal, M. B. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-97664-2 · Cited by 15
An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms
Duffy, D., Mottez, E., Ainsworth, S., Buivan, T.-P., Baudin, A., Vray, M., Reed, B., Fontanet, A. L., Rohel, A., Petrov–Sanchez, V., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183084 · Cited by 13
Tools to Alleviate the Drug Resistance in Mycobacterium tuberculosis
Rabaan, A. A., Mutair, A. S. A., Albayat, H., Alotaibi, J., Sulaiman, T., Aljeldah, M. M., Shammari, B. R. A., Alfaraj, A. H., Fares, M. A. A., Alwarthan, S. M., et al. (2022) · Molecules · doi:10.3390/molecules27206985 · Cited by 15
Yezli, S., Yassin, Y. M., Mushi, A., Maashi, F., Abdelmalek, N. M., Awam, A. H., & Alotaibi, B. M. (2023) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-023-04596-8 · Cited by 12
“All sputum samples were processed after Hajj using the Xpert MTB/RIF assay as described previously [12].”
MethodXpert MTB/RIF False Detection of Rifampin-Resistant Tuberculosis from Prior Infection
Kelly, J. D., Lin, S.-Y. G., Barry, P. M., Keh, C. E., Higashi, J. M., & Metcalfe, J. Z. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1500le · Cited by 12
“Xpert test errors in rifampin-resistance determination have been documented, in particular in the setting of low pretest probability (6, 7).”
BackgroundJahan, H., Jhora, S. T., Habib, Z. H., Yusuf, M. A., Ahmed, I., Farzana, A., & Parveen, R. (2016) · Journal of Tuberculosis Research · doi:10.4236/jtr.2016.41007 · Cited by 12
“[4] showed that GeneXpert was detected 62 (58%) Mycobacterium tuberculosis out of 107 clinical sputum samples which was similar to the present study.”
BackgroundMethodResultInfluentialHirasen, K., Berhanu, R. H., Evans, D. H., Rosen, S. B., Sanne, I., & Long, L. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205463 · Cited by 12
Kabugo, J., Namutebi, J., Mujuni, D., Nsawotebba, A., Kasule, G. W., Musisi, K., Kigozi, E., Nyombi, A., Lutaaya, P., Kangave, F., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251691 · Cited by 12
Rahman, S. M. M., Ather, M. F., Nasrin, R., Hoque, M. A., Khatun, R., Rahman, T., Uddin, M. K. M., Ahmed, S., & Banu, S. (2022) · Diagnostics · doi:10.3390/diagnostics12020410 · Cited by 12
“tuberculosis complex and resistance to rifampicin (RIF) [13,14].”
BackgroundSilva, D. R., Müller, A. M., Tomasini, K. D. S., Dalcin, P. D. T. R., Golub, J. E., & Conde, M. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107576 · Cited by 12
“This is a fully automated molecular diagnostic test that can simultaneously detect Mycobacterium tuberculosis complex DNA and mutations associated with rifampicin resistance directly from sputum specimens in less than 2 hours, minimizing staff manipulation and biosafety risk [17].”
Use of nanotechnology for infectious disease diagnostics: application in drug resistant tuberculosis
Karunaratne, E., Wijenayaka, L. A., Wijesundera, S. S., de Silva, K. M. N., Adikaram, C. P., & Perera, J. A. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4259-x · Cited by 12
“MTb and RIF resistance directly from sputum as well as extra pulmonary samples [19, 20].”
Background
Metadata
- Authors
- Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., Safi, H., Blakemore, R., Lan, N. T. N., Jones-López, E. C., Levi, M., Burday, M., Ayakaka, I., Mugerwa, R. D., McMillan, B., Winn-Deen, E., Christel, L., Dailey, P., Perkins, M. D., Persing, D. H., & Alland, D.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Cepheid (United States) (US)
- Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey
- FIND (CH)
- Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
- Montefiore Medical Center (US)
- Makerere University (UG)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 48
- Issue
- 1
- Pages
- 229-237
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2812290
- OpenAlex
- W2112022845
- Cited by
- 914
- References
- 59
- Citations by year
- 2026: 29 · 2025: 38 · 2024: 35 · 2023: 33 · 2022: 36 · 2021: 45 · 2020: 65 · 2019: 55 · 2018: 61 · 2017: 62 · 2016: 63 · 2015: 62 · 2014: 74 · 2013: 71 · 2012: 62
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R41AI052523, R42AI052523, R42-AI52523, R41-AI52523)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis detection, rifampicin resistance, Xpert MTB/RIF, point-of-care testing, real-time PCR, sputum, detection limit, nontuberculous mycobacteria, retreatment tuberculosis, tuberculosis diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Sputum, Tuberculosis, Uganda, Vietnam, Polymerase Chain Reaction, Point-of-Care Systems, Drug Resistance, Bacterial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.